CD20 as a target for therapeutic type I and II monoclonal antibodies.
about
Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemiaImmune Modulation in Hematologic MalignanciesLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsNew antibody approaches to lymphoma therapyIn silico designing, cloning, and heterologous expression of novel chimeric human B lymphocyte CD20 extra loop.Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia.Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.Proteomic analysis of S-acylated proteins in human B cells reveals palmitoylation of the immune regulators CD20 and CD23.Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumabOne target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.Haematological malignancies: at the forefront of immunotherapeutic innovation.7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cellsFunctional recombinant extra membrane loop of human CD20, an alternative of the full length CD20 antigenSingle nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma.Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.Hairy cell leukemia - immunotargets and therapiesChronic lymphocytic leukemia therapy: new targeted therapies on the wayEnhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.Modulation of tumor immunity by therapeutic monoclonal antibodies.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Rituximab for chronic lymphocytic leukemia.Targeted drug delivery for cancer therapy: the other side of antibodies.Mechanisms of action of CD20 antibodies.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.The role of monoclonal antibodies in the treatment of lymphomas.Lymphoproliferative disorders in immunocompromised individuals and therapeutic antibodies for treatment.Novel antibodies targeting immune regulatory checkpoints for cancer therapy.Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.The MS4A family: counting past 1, 2 and 3.
P2860
Q26781163-0FC905A5-D132-4D95-B7FF-85546FC6DB6DQ26796307-A4C05D9A-00C9-47D6-8D70-6874D3E5B5BAQ26849243-5DD4C88B-9D19-4D47-BCF3-D4659CE5FC51Q27022373-5918ACC0-C837-4C8B-BF19-656C8C65CB3BQ30389864-E21A6AF6-DBD3-430C-93AA-9F0B4FE9F02DQ33683659-304314E2-8113-4023-852C-63C6089462DBQ33708995-3E388BD9-7BAF-45BB-B398-4A2BD9262055Q33838871-2C12529F-C49E-4EFD-B482-A71692003EA5Q34277857-6F037A69-56AC-4513-B1DB-4D41D4283734Q34440110-3CA6DC08-A052-4C86-B35D-501A8442B29FQ34480345-F0D07C84-13E3-4788-8BBC-3501DFEE7B4BQ35076449-25E7863A-D389-4C84-83C8-EE1B41326E41Q35569418-A8F124FB-D2CE-45FF-8C55-70154FA14B21Q35717890-28632B25-9D0C-4D78-BA98-7E9E60D12110Q35880618-34CAEDA7-C1D5-4AC8-8D29-F88CCD827101Q35992488-984521BE-13C8-4E90-B32E-2DE0F7B29960Q36161443-E12988D4-22B2-4574-9595-0976103FC484Q36216038-05AAE907-56C9-4F6D-854D-E87E085CC3E8Q36777171-434DE7ED-717A-4F5F-AA6F-96A8213AEE9DQ36940760-DC3F1F49-3D22-49C8-8E44-06B174913325Q36998859-52F1F998-E8E1-45DD-9EE2-C12612FB1FA6Q37031666-1E178067-39CA-4B08-BCC9-FC31FC3E9671Q37113544-829E8D0D-65F1-4023-8688-276435EBC6C5Q37114367-FDD8E7F2-37E4-4057-A91E-8B5887134CC2Q37810901-2CC62D20-CBAE-41ED-A1DA-20FA968D900DQ37832438-952D1EF7-04E7-473F-93C7-569DFD38E862Q37913356-A7357DB8-BDC1-49E5-9AD7-0C8CAF17FDF2Q37988562-C3DE270C-6252-44F0-A200-9C1E9484047AQ38058816-09C99D5E-678B-43A9-9188-42AD9B367133Q38066195-B38D5FB7-94F7-474E-A9C4-51C4FAD0E1ADQ38068494-81EB92A9-D364-4154-9141-7AE4F8A79134Q38068932-5B565805-B77F-40FC-9467-470C76C81362Q38069595-2250850B-69D1-4FE4-8D3B-0DBE3A7E0958Q38096060-B1727856-20B3-436C-8901-897EBC1AD347Q38108836-323EAAF1-E4C1-4F9C-8771-D05896B3FA41Q38121632-A2C94A9D-8B19-45C4-B788-F7F6719A83EAQ38205856-E8F54F3E-2B1F-4B03-9D10-E03141B386FFQ38218786-3EEC814A-7BED-473B-A0B0-E21AAF23ED2EQ38221686-6E3EBD2A-2485-42CC-9C08-4E99FCB9ABD3Q38401877-641EDCF9-E8F5-4D90-8D9F-7F99C8319644
P2860
CD20 as a target for therapeutic type I and II monoclonal antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CD20 as a target for therapeutic type I and II monoclonal antibodies.
@en
CD20 as a target for therapeutic type I and II monoclonal antibodies.
@nl
type
label
CD20 as a target for therapeutic type I and II monoclonal antibodies.
@en
CD20 as a target for therapeutic type I and II monoclonal antibodies.
@nl
prefLabel
CD20 as a target for therapeutic type I and II monoclonal antibodies.
@en
CD20 as a target for therapeutic type I and II monoclonal antibodies.
@nl
P2093
P1476
CD20 as a target for therapeutic type I and II monoclonal antibodies
@en
P2093
Claude H T Chan
Martin J Glennie
Ruth R French
Stephen A Beers
P304
P356
10.1053/J.SEMINHEMATOL.2010.01.001
P50
P577
2010-04-01T00:00:00Z